<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274752</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00349</org_study_id>
    <nct_id>NCT03274752</nct_id>
  </id_info>
  <brief_title>Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction</brief_title>
  <acronym>CARE-AMI</acronym>
  <official_title>Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction (CARE-AMI): a Randomized Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the off-target effect of paroxetine to reverse cardiac remodeling and
      improve left ventricular ejection fraction in patients after acute myocardial infarction.
      Half of the participants will receive paroxetine, while the other half will receive placebo
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac remodeling is characterized by a composite of structural, geometric, molecular, and
      functional changes of the myocardium, and is an important determinant of heart failure and
      cardiovascular outcome in survivors of acute myocardial infarction. Progression of heart
      failure secondary to the remodeling process results from dysregulation of the G
      protein-coupled receptor (GPCR). Excessive adrenergic drive in patients with heart failure
      results in an enhanced activation of GPCR kinases (GRKs) that is considered to have a central
      role in adverse cardiac remodeling after ischemic injury. The selective Serotonin reuptake
      inhibitor paroxetine specifically binds to the catalytic domain of GRK2 as an off-target
      effect, and has been shown to reverse cardiac remodeling and increase left ventricular
      ejection fraction in a mouse model. The effect was observed at serum levels achieved with
      standard dosages of paroxetine, and was robust in mice with and without concomitant heart
      failure treatment, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the change of left ventricular ejection fraction (LVEF)</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Assessment by cardiac magnetic resonance imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in change in left left-ventricular end-diastolic volume (LVEDV)</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Assessment by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in left left-ventricular end-systolic volume (LVESV)</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Assessment by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in late-enhancement</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>Assessment by cardiac magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in LVEF between baseline and 12 weeks, and 12 months, respectively</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Assessment by transthoracic echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events</measure>
    <time_frame>12 weeks and 12 months after randomization</time_frame>
    <description>Cardiac death, myocardial infarction, repeat hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms of heart failure</measure>
    <time_frame>12 weeks and 12 months after randomization</time_frame>
    <description>Assessed by New York Heart Association (NYHA) categorization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiac Remodeling</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule QD per os for 13 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.</description>
    <arm_group_label>Paroxetine</arm_group_label>
    <other_name>Deroxat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anterior wall ST-segment elevation myocardial infarction

          -  Primary percutaneous coronary intervention (PCI) within 24 hours of symptom onset

          -  Left ventricular ejection fraction â‰¤ 45% within 48-96 hours after primary PCI
             (transthoracic echocardiography)

        Exclusion Criteria:

          -  Female patients at reproductive age (&lt;50 years)

          -  Known intolerance to paroxetine

          -  Inability to provide informed consent

          -  Currently participating in another trial before reaching first endpoint

          -  Current medical therapy with MAO-blocker (during, 14 days before, and 14 days after
             treatment with MAO-blocker), lithium, thioridazide, or pimozide

          -  Concomitant tamoxifen intake

          -  Previous myocardial infarction

          -  Previous revascularization procedure (percutaneous coronary intervention or coronary
             artery bypass grafting).

          -  Contraindication to cardiac magnetic resonance imaging

          -  Obvious or questionable inability to appropriately cooperate (alcohol, drugs etc.)

          -  Relevant nephropathy or hepatopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Pilgrim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital, Department of Cardiology, Freiburgstrasse 10, CH-3010 Bern, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rene Vollenbroich, MD, MPP</last_name>
    <phone>+41 31 632 11 11</phone>
    <email>rene.vollenbroich@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bern University Hospital, Department of Cardiology</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Pilgrim, MD</last_name>
      <phone>+41 31 632 08 27</phone>
      <email>thomas.pilgrim@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, Tesmer JJ, Koch WJ. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med. 2015 Mar 4;7(277):277ra31. doi: 10.1126/scitranslmed.aaa0154.</citation>
    <PMID>25739765</PMID>
  </reference>
  <reference>
    <citation>Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000 Jun 27;101(25):2981-8. Review.</citation>
    <PMID>10869273</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

